An open-label, phase 1a/b study of AB248, a CD8+selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors

被引：0
|
作者：
Buchbinder, Elizabeth I.
Spigel, David R.
Albany, Costantine
Chisamore, Michael
Moynihan, Kelly D.
Liu, Xiaohan
DelNagro, Christopher
Axt, Matt
Pirzkall, Andrea
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT250
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT250
引用
收藏
页数：2
相关论文
共 50 条
  • [41] AURELIO-04: A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF SOT101 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH SELECTED ADVANCED SOLID TUMORS
    Champiat, Stephane
    Marabelle, Aurelien
    Davar, Diwakar
    Grell, Peter
    Ouali, Kaissa
    Patrikidou, Anna
    Schoenenberger, Andreu
    Jelinkova, Lenka Palova
    Adkins, Irena
    Tillmanns, Sascha
    Kiemle-Kallee, Joachim
    Sachse, Richard
    Garralda, Elena
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A749 - A749
  • [42] A multicenter, open-label, phase 1a/b study of HC-7366, a modulator of integrated stress response (ISR) kinase GCN2 in subjects with advanced solid tumors
    Pelster, Meredith
    Torre, Marcio
    Kannan, Geoffrey Sumithran
    Gargano, Michele Anne
    Mattson, Paulette
    Rathmann, Blaine
    Bose, Nandita
    Iglesias, Jose Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
    Thein, Kyaw Z.
    Fu, Siqing
    Janku, Filip
    Tsimberidou, Apostolia M.
    Piha-Paul, Sarina A.
    Karp, Daniel D.
    Shah, Jatin
    Milton, Denai R.
    Gong, Jing
    Sulovic, Selma
    McQuinn, Lacey
    Stephen, Bettzy A.
    Colen, Rivka R.
    Carter, Brett W.
    Meric-Bernstam, Funda
    Naing, Aung
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2022, 5 (01) : 10 - 12
  • [44] A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.
    Piha-Paul, Sarina Anne
    Amin, Alpesh
    Kovacs, Christina
    Magley, Andrea
    Das Purkayastha, D.
    Zhuo, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab
    Moser, Justin C.
    Opyrchal, Mateusz
    Rivera, Ildefonso Rodriguez
    Curti, Brendan D.
    Puzanov, Igor
    Sosman, Jeffrey A.
    Bilen, Mehmet Asim
    Morris, Kristin
    Nirschl, Christopher J.
    Park, Saero
    Bruno, Marissa
    Windt, Paul
    Subramanian, Kulandayan K.
    Schonborn-Kellenberger, Oliver
    Chopra, Sameer
    Isaacs, Randi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
    Lakhani, Nehal J.
    Chow, Laura Q. M.
    Gainor, Justin F.
    LoRusso, Patricia
    Lee, Keun-Wook
    Chung, Hyun Cheol
    Lee, Jeeyun
    Bang, Yung-Jue
    Hodi, Frank Stephen
    Kim, Won Seog
    Santana-Davila, Rafael
    Fanning, Philip
    Squifflet, Pierre
    Jin, Feng
    Kuo, Tracy C.
    Wan, Hong, I
    Pons, Jaume
    Randolph, Sophia S.
    Messersmith, Wells A.
    LANCET ONCOLOGY, 2021, 22 (12): : 1740 - 1751
  • [47] Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.
    McDermott, Jessica Dreger
    Subbiah, Vivek
    Beck, Joseph Thaddeus
    Doi, Toshihiko
    Hirohashi, Tomoko
    Ingram, Kim
    Li, Ruifeng
    Abbruzzese, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS270 - TPS270
  • [48] A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
    Beckermann, Kathryn E.
    Patnaik, Amita
    Winer, Ira
    Tan, Winston
    Bashir, Babar
    Kyriakopoulos, Christos E.
    Sweis, Randy F.
    Chamberlain, Marc
    Rini, Brian I.
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (02) : 179 - 184
  • [49] A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
    Kathryn E. Beckermann
    Amita Patnaik
    Ira Winer
    Winston Tan
    Babar Bashir
    Christos E. Kyriakopoulos
    Randy F. Sweis
    Marc Chamberlain
    Brian I. Rini
    Investigational New Drugs, 2024, 42 : 179 - 184
  • [50] An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis
    Necchi, Andrea
    Giannatempo, Patrizia
    Raggi, Daniele
    Mariani, Luigi
    Colecchia, Maurizio
    Fare, Elena
    Monopoli, Francesco
    Calareso, Giuseppina
    Ali, Siraj M.
    Ross, Jeffrey S.
    Chung, Jon H.
    Salvioni, Roberto
    EUROPEAN UROLOGY, 2019, 75 (01) : 201 - 203
12345